Pediatrix Medical Group (NYSE:MD) Price Target Raised to $15.00 at Deutsche Bank Aktiengesellschaft

Pediatrix Medical Group (NYSE:MD) had its target price increased by Deutsche Bank Aktiengesellschaft from $9.00 to $15.00 in a report released on Monday morning, Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a hold rating on the stock.

A number of other brokerages have also commented on MD. Mizuho upped their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Monday. StockNews.com upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Truist Financial upped their price target on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research note on Monday. UBS Group boosted their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a report on Friday, August 9th. Finally, Jefferies Financial Group raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and boosted their price objective for the company from $8.00 to $14.00 in a report on Thursday, September 26th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $14.90.

Pediatrix Medical Group Stock Up 0.3 %

MD traded up $0.05 during trading on Monday, hitting $15.19. The company had a trading volume of 33,721 shares, compared to its average volume of 869,003. The company has a market capitalization of $1.30 billion, a PE ratio of -4.95, a PEG ratio of 2.36 and a beta of 1.55. Pediatrix Medical Group has a one year low of $6.62 and a one year high of $15.43. The firm’s 50-day moving average price is $11.70 and its 200 day moving average price is $9.45. The company has a quick ratio of 1.38, a current ratio of 1.58 and a debt-to-equity ratio of 0.86.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.29 EPS. As a group, equities analysts expect that Pediatrix Medical Group will post 1.19 earnings per share for the current year.

Insider Activity at Pediatrix Medical Group

In related news, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the sale, the chief executive officer now owns 170,001 shares in the company, valued at approximately $1,834,310.79. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the sale, the chief executive officer now owns 170,001 shares in the company, valued at approximately $1,834,310.79. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO C Marc Richards sold 32,562 shares of the firm’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $10.08, for a total transaction of $328,224.96. Following the sale, the chief financial officer now owns 192,785 shares of the company’s stock, valued at $1,943,272.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,100 shares of company stock valued at $701,889 over the last ninety days. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Pediatrix Medical Group by 1.6% in the first quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after buying an additional 164,333 shares during the period. Rubric Capital Management LP increased its stake in shares of Pediatrix Medical Group by 797.0% in the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after buying an additional 7,241,400 shares during the period. Boston Partners increased its stake in shares of Pediatrix Medical Group by 34.0% in the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after buying an additional 453,254 shares during the period. Dana Investment Advisors Inc. raised its stake in Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after buying an additional 455,785 shares in the last quarter. Finally, Brandes Investment Partners LP grew its stake in Pediatrix Medical Group by 12.8% in the second quarter. Brandes Investment Partners LP now owns 735,068 shares of the company’s stock worth $5,438,000 after purchasing an additional 83,588 shares during the period. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.